Akaal Pharma
Melbourne, Australia· Est.
Australian biotech developing selective S1P1 modulators for dermatology and autoimmune indications.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Australian biotech developing selective S1P1 modulators for dermatology and autoimmune indications.
ImmunologyDermatologyNeurology
Technology Platform
Selective small‑molecule modulators of the S1P1 receptor derived from a proprietary library of >100 novel compounds, emphasizing high receptor selectivity and favorable pharmacokinetics.
Opportunities
Advancing Oakp‑11 into later‑stage trials for autoimmune indications and neuropathic pain, and leveraging Takp‑119 as a non‑steroidal topical therapy for atopic dermatitis, could unlock large market opportunities and attract strategic partnerships.
Risk Factors
Clinical development risk, especially demonstrating superiority over existing S1P1 agents, and potential regulatory hurdles for novel oral and topical formulations.
Competitive Landscape
Existing S1P1 modulators (e.g., fingolimod, siponimod) have safety and efficacy limitations; Akaal’s high‑selectivity, low‑lymphopenia candidates aim to differentiate on safety, tolerability, and route‑of‑administration.